Deloitte has identified a potential $527 billion increase in U.S. women’s healthcare spending by 2030, driven by earlier disease detection, preventive interventions and improved management of chronic conditions. The analysis outlines opportunities to address unmet healthcare needs while shifting care delivery toward more proactive, personalized approaches.
Using its Future of Health actuarial modeling framework, Deloitte analyzed five years of medical and pharmacy claims data covering nearly 60 million individuals. The assessment examined 22 healthcare areas, identifying brain health, pelvic health, cardiovascular disease, and musculoskeletal and autoimmune conditions as areas with significant unmet needs.
The $527 billion estimate represents potential additional healthcare spending under a more proactive care scenario, rather than guaranteed revenue or projected cost savings.
Jen Radin, principal at Deloitte & Touche, emphasized that realizing this opportunity depends on addressing existing barriers to timely diagnosis and coordinated treatment.
"It could be constrained if diagnosis remains delayed, care stays fragmented, or emerging tools are not validated, integrated into workflows, and linked to appropriate follow-up," Radin said.
Digital health technologies could support earlier identification of health risks across women's life stages, particularly during reproductive years and midlife, when preventive interventions may help reduce disease progression.
"Digital tools such as wearables, blood-based biomarkers, AI-enabled imaging, remote monitoring and virtual specialty programs could signal issues and support care at any point," Radin explained.
For healthcare providers, Deloitte highlights the importance of integrating clinical information across specialties to support personalized care. Health insurers could facilitate this transition by expanding access to diagnostics, preventive services, remote monitoring and virtual specialty consultations.
Industry initiatives are already exploring these approaches. Teal Health and UC Davis Health announced a pilot evaluating at-home cervical cancer screening integration into routine clinical workflows for women aged 30–65. Teal's sample-collection device received FDA authorization in May 2025.
Separately, Deloitte's longer-term modeling suggests that improved prevention and disease management could potentially extend women's health span by up to 20 years, although this estimate uses different assumptions and time horizons.
The findings indicate opportunities for healthcare organizations to develop integrated preventive services that address unmet needs while supporting sustained demand for women's healthcare solutions.
Click here for the original news story.
